Article

Laser photocoagulation still standard of care for diabetic maculopathy

The Early Treatment Diabetic Retinopathy Study (EDTRS) laser is still the standard of care of diabetic maculopathy. There is enthusiastic support for the potential of pharmaceutical therapy, using anti-vascular endothelial growth factor agents, however, the laser remains the gold standard, said Francesco Bandello, MD, of the University of Udine, Udine, Italy.

The Early Treatment Diabetic Retinopathy Study (ETDRS) laser isstill the standard of care of diabetic maculopathy. There isenthusiastic support for the potential of pharmaceutical therapy,using anti-vascular endothelial growth factor agents, however,the laser remains the gold standard, said Francesco Bandello, MD,of the University of Udine, Udine, Italy.

Focal and grid techniques are used to address diabeticmaculopathy, and with both come the complications of laser burns,progressive retinal pigment epithelial atrophy, progressiveenlargement of laser scars, and central scotomas.

The classic laser treatment was modified to circumvent thesecomplications and reduce tissue damage with the hopes thatsubthreshold diode micro pulse laser and the PASCAL system thatapplies short pulses to the retinal tissue would beefficacious.

"Theoretically,” Dr. Bandello reported, "these systems should havebeen able to produce fewer side effects and less damage whilemaintaining the efficacy of the classic treatment. However, themilder laser treatment was not as effective 12 months after thetreatment compared with the conventional laser.”

The role of optical coherence tomography (OCT) also has beeninvestigated to determine when laser treatment should be appliedin patients with diabetic maculopathy. A meta-analysis of thistopic found that if there is no doubt about a diagnosis ofmaculopathy, OCT is not needed. In cases in which there is doubtabout the presence of edema or the macular thickness is less than250 µm, there is no need for laser treatment; when themacula is more than 300 µm, laser treatment is indicated,according to Dr. Bandello.

"Despite the potential theoretic advantages offered by the newlasers, the ETDRS technique still appears to be the mosteffective way to treat diabetic macular edema (DME). The resultsof long-term trials of these lasers are needed,” Dr. Bandellosaid. "There is also the potential for the combining of drugs andlaser treatment to improve the effect of treatment overall of DMEand reduce the side effects.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.